Medicare AdvantagePrior AuthMedium impact
MA08.073s, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology, Pharmacy·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
This is a new Medicare Advantage policy (MA08.073s) effective July 1, 2025, establishing coverage and billing guidelines for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors. The billing team must verify prior authorization requirements, covered medications, and any quantity limits or frequency restrictions for these ophthalmic injectable drugs before processing claims.
Action Required
By June 15, 2025: Obtain and review the complete policy text from the source URL to identify specific HCPCS J-codes for covered VEGF antagonist medications, prior authorization requirements, and any quantity or frequency limits. Billing team must: (1) Update billing system rules to require prior authorization for intravitreal VEGF injections per policy specifications; (2) Create a reference document listing covered medications and any excluded drugs; (3) Train billing and clinical staff on documentation requirements for medical necessity; (4) Communicate with ophthalmology providers about any changes to their billing workflow. Update encounter forms or EMR templates to ensure providers document the specific indication and medication being injected. Failure to obtain required prior authorization will result in claim denials. Note: Specific billing codes and detailed policy requirements are not visible in the provided policy metadata; obtain full policy text to complete implementation.